% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • beachbarbob beachbarbob Jul 2, 2006 2:07 PM Flag

    i still cannot believe it - nerd

    Well if you have access to Berstien Research why don't you list the comparison they did via their 3/02/06 research report page 31 and adjust the data for pfizer dropping indiplon and the 15Mg debacle, looks to me lunesta has the advantage. If their is no 15Mg dose their is no real Indiplon franchise just a me too $150M in annual sales drug via IR.

46.90+0.66(+1.43%)Apr 28 4:00 PMEDT